Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Beat The Street With SI Traders -- Ignore unavailable to you. Want to Upgrade?

To: pocotrader who wrote (1175)	7/25/2009 7:58:01 PM
From: heinz44	Respond to of 233964

GAP...............because getting close The company has been informed by the OHRI that initial results from the OHRI test program, being the effect of PhG-alpha-1 at a range of dose concentrations on the growth rate of ovarian cancer cells, are expected in or prior to the first week of August, 2009, following completion of a full statistical analysis. Additionally, the company is advised by the OHRI that the second phase of the test program, which will evaluate the effect of PhG-alpha-1 on cell invasion and mobility in a number of different ovarian cancer cell lines, is about to commence.